Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | OGG1 | O15527 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.43 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.41 |
| ▸ | INPP5B | P32019 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29510856 | 0.85 | HTT (0.50) | HTTALDH1A1KDM4EHPGDTDP1 | |
| SCHEMBL1027272 | 0.85 | HTT (0.50) | HTTALDH1A1KDM4EHPGDTDP1 | |
| SCHEMBL719618 | 0.85 | HTT (0.50) | HTTALDH1A1KDM4EHPGDTDP1 | |
| SCHEMBL60472 | 0.85 | INPPL1 (0.59) | HTTALDH1A1KDM4EHPGDTDP1 | |
| SCHEMBL547016 | 0.85 | L3MBTL1 (0.50) | HTTALDH1A1KDM4EHPGDTDP1 | |
| SCHEMBL29618036 | 0.85 | INPPL1 (0.59) | HTTALDH1A1KDM4EHPGDTDP1 | |
| SCHEMBL29175021 | 0.83 | HTT (0.49) | HTTALDH1A1KDM4EHPGDTDP1 | |
| Potassium SCHEMBL30820065 | 0.83 | INPPL1 (0.57) | HTTALDH1A1KDM4EHPGDTDP1 | |
| SCHEMBL2544707 | 0.83 | INPPL1 (0.57) | HTTALDH1A1KDM4EHPGDTDP1 | |
| SCHEMBL11322823 | 0.83 | INPPL1 (0.57) | HTTALDH1A1KDM4EHPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037077-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2017-02-09 | — | — | US | disclosed |
| US-20170037077-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2017-02-09 | — | — | US | disclosed |
| CN-105753900-A | Synthesis method of aromatic amide phosphate compound and flame retardant containing compound | 和夏化学(太仓)有限公司 | 2016-07-13 | — | — | CN | disclosed |
| US-8946243-B2 | Compounds and methods for the treatment of viral infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-02-03 | — | — | US | disclosed |
| US-20110184003-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH (US) | 2011-07-28 | — | — | US | disclosed |
| EP-2274311-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTION | Government of the United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009142827-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTION | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037077-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | HTT 2179/4885ALDH1A1 1431/4885KDM4E 3890/4885 |
| US-20110184003-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTION | TPMT, TYMP, MTAP | HTT 4287/4885ALDH1A1 877/4885KDM4E 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.